众生药业(002317) - 2024 Q2 - 季度业绩预告

Financial Performance - The company expects a net profit attributable to shareholders of approximately 80 million to 100 million yuan, representing a decrease of 61.64% to 52.05% compared to the same period last year[11]. - The net profit after deducting non-recurring gains and losses is estimated to be between 170 million and 190 million yuan, down by 25.89% to 17.17% year-on-year[11]. - The basic earnings per share are projected to be between 0.10 yuan and 0.12 yuan, compared to 0.26 yuan per share in the same period last year[11]. - Non-recurring gains and losses are expected to impact net profit by approximately 80 million to 100 million yuan[6]. - The fair value of trading financial assets held by the company has decreased compared to the beginning of the period, contributing to the decline in net profit attributable to shareholders[5]. Product and Market Impact - The company's core product, the Compound Thrombus Tong series, was successfully selected in the national centralized procurement of traditional Chinese medicine, impacting short-term performance due to price reductions[12]. Legal Matters - The company is involved in a lawsuit regarding a disagreement with Shanghai Woli Biotechnology Co., Ltd. over the supply and production of raw materials and formulations[4]. - The company has made provisions for expected liabilities based on a first-instance judgment in an ongoing lawsuit, which has also affected net profit[14]. Disclosure and Investor Relations - The financial data presented is preliminary and has not been audited by an accounting firm; detailed financial data will be disclosed in the 2024 semi-annual report[15]. - The company emphasizes the importance of timely information disclosure and advises investors to be aware of investment risks[15].